@article{21421,
  keywords = {Adult, Animals, Anti-Inflammatory Agents, Non-Steroidal, Antifibrinolytic Agents, Behcet Syndrome, Child, Child, Preschool, Graft vs Host Disease, Hemorheology, HIV Infections, Humans, Infant, Leishmaniasis, Cutaneous, leprosy, Mice, Mice, Nude, Pentoxifylline, Phosphodiesterase Inhibitors, Sarcoidosis, Skin Diseases, Tumor Necrosis Factor-alpha, Vascular Diseases},
  author = {Zargari O},
  title = {Pentoxifylline: a drug with wide spectrum applications in dermatology.},
  abstract = {<p>Pentoxifylline (PTX) is a methylxanthine derivative with a variety of anti-inflammatory effects. Currently, PTX is approved by the Food and Drug Administration for the treatment of intermittent claudication, but studies have shown that it has a variety of physiological effects at the cellular level, which may be important in treating a diverse group of diseases.</p>},
  year = {2008},
  journal = {Dermatology online journal},
  volume = {14},
  pages = {2},
  month = {2008 Nov 15},
  issn = {1087-2108},
  language = {eng},
}